<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>New therapies for angina pectoris</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">New therapies for angina pectoris</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">New therapies for angina pectoris</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roger J Laham, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention (PCI), a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed.</p><p>Many of these patients are not candidates for revascularization by PCI or coronary artery bypass graft surgery (CABG) because of one or more of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unsuitable anatomy, such as diffuse coronary disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One or several prior PCIs or CABGs, which may limit further benefit or preclude further revascularization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of vascular conduits for CABG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severely impaired left ventricular function in patients with previous CABG or PCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent diseases that increase perioperative or postoperative morbidity or mortality (eg, cerebrovascular disease, advanced complications of diabetes, chronic kidney disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age, often in combination with other factors. </p><p></p><p>In addition, a substantial proportion of patients undergoing PCI or CABG do not achieve complete revascularization. Many of these patients continue to experience residual anginal symptoms or myocardial ischemia despite maximal medical therapy. (See  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a>.)</p><p>The newer medical and mechanical therapies that are currently being evaluated for treating patients with refractory angina will be reviewed here [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">MEDICAL THERAPIES</span><span class="headingEndMark"> — </span>A number of medical therapies are being evaluated for the treatment of refractory angina. Only <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> has been approved for use in the United States.</p><p class="headingAnchor" id="H3"><span class="h2">Ranolazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a> was approved by the United States Food and Drug Administration (FDA) in 2006 for management of chronic stable angina. Although initially thought to act by partial inhibition of fatty acid oxidation, it was later realized that ranolazine had that effect only at serum levels not achieved with the usual dosing.</p><p>A more important mechanism for <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> may be the prevention of both calcium overload and the subsequent increase in diastolic tension due to inhibition of late inward sodium channel [<a href="#rid4">4,5</a>]. Since this sodium channel frequently fails to inactivate in a number of important myocardial disease states such as ischemia and hypertrophy, excess entry of sodium ions leads to activation of the sodium/calcium exchanger, thereby raising calcium concentration [<a href="#rid6">6</a>]. Given the normal rapid inaction of the late inward sodium channel in normal myocytes, the drug does not exert a significant effect on the normal myocardium at usual dosages. This potentially increases its therapeutic window.</p><p>The initial dose of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> is 500 mg twice daily. For patients who remain symptomatic, 1000 mg twice daily may be used.</p><p class="headingAnchor" id="H4"><span class="h3">Acute coronary syndrome</span><span class="headingEndMark"> — </span>A separate issue from the efficacy of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> for symptom control is whether it might improve cardiovascular outcomes. The lack of such benefit was demonstrated in the MERLIN-TIMI 36 trial in which over 6000 patients with an acute coronary syndrome were randomly assigned to placebo or to ranolazine (initiated intravenously and followed by oral therapy of extended release 1000 mg twice daily) [<a href="#rid7">7</a>]. At one year, there was no significant difference between the two groups in the primary composite, efficacy end point of cardiovascular death, myocardial infarction (MI), or recurrent ischemia or any of the safety end points including total mortality or symptomatic documented arrhythmias.</p><p class="headingAnchor" id="H5"><span class="h3">Stable angina</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> in patients with chronic stable angina has been demonstrated in several randomized trials [<a href="#rid8">8-10</a>]. The following observations illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In the MARISA trial, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> monotherapy resulted in a dose-dependent increase in pain-free exercise duration and time to angina in 191 patients, with a 1000 mg twice daily dose being more effective than a lower dose [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CARISA trial, 823 patients receiving background antianginal therapy (calcium channel blocker or <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>) were randomly assigned to placebo or one of two doses of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> (750 or 1000 mg twice daily) [<a href="#rid8">8</a>]. After 12 weeks of therapy, both doses of ranolazine significantly increased symptom-limited exercise duration, time to onset of angina, and (at peak ranolazine blood level) time to ST segment depression, and reduced angina frequency by 0.8 and 1.2 episodes per week, compared to placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the ERICA trial, 565 stable patients with more than three anginal attacks per week were randomly assigned to either <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> (1000 mg/day) or placebo [<a href="#rid9">9</a>]. All patients were taking 10 mg of <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> per day and were allowed to be on long-acting nitrates but not beta blockers; the patients had 5.63 episodes of angina per week at baseline. Ranolazine significantly improved the primary end point of anginal episodes per week compared to placebo (2.88 versus 3.31).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the TERISA trial, 949 patients with diabetes and stable angina treated with one to two antianginal drugs were randomly assigned to <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> or placebo for eight weeks [<a href="#rid11">11</a>]. Weekly angina frequency was lower with ranolazine (3.8 versus 4.3 episodes; p = 0.008) as was weekly sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> use (1.7 versus 2.1 doses; p = 0.003). Although statistically significant and in agreement with findings in other ranolazine studies, the absolute effects of ranolazine in this study are modest.</p><p></p><p class="headingAnchor" id="H1135490115"><span class="h4">Incomplete revascularization after PCI</span><span class="headingEndMark"> — </span>Many patients with chronic stable angina do not receive complete revascularization at the time of percutaneous coronary intervention (PCI). The issue of whether <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> might improve outcomes in such patients was evaluated in the RIVER-PCI trial, which randomly assigned 2651 patients to ranolazine or placebo after incomplete revascularization with PCI [<a href="#rid12">12</a>]. There was no difference in the rate of the primary efficacy end point (time to first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization) between the two groups (26 versus 28 percent; hazard ratio 0.95, 95% CI 0.82-1.10) after a median follow-up of 643 days.</p><p class="headingAnchor" id="H6"><span class="h3">Unstable angina</span><span class="headingEndMark"> — </span>A different population was studied in the MERLIN-TIMI 36 trial cited above of patients with an acute coronary syndrome [<a href="#rid7">7,13</a>]. In the subset of 3565 patients who had prior chronic angina, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> significantly reduced the primary end point of cardiovascular death, MI, and recurrent ischemia due entirely to a significant reduction in recurrent ischemia (hazard ratio [HR] 0.78, 95% CI 0.67-0.91) [<a href="#rid13">13</a>]. There was also an almost significant trend toward a lower rate of worsening angina (HR 0.77, 95% CI 0.55-1.00) and a significant improvement in exercise duration on a treadmill (514 versus 482 seconds).</p><p class="headingAnchor" id="H8"><span class="h3">Glycometabolic effect</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> in the MERLIN-TIMI-36 trial population resulted in a statistically significant 0.3 percent absolute reduction in HbA1c levels that was even more pronounced in patients with diabetes mellitus. There may also have been a reduction in progression to overt clinical diabetes as defined by increase in fasting blood sugar above 110 mg/dL (6.1 mmol/liter) [<a href="#rid14">14</a>]. The mechanism of this effect is unclear.</p><p class="headingAnchor" id="H9"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Since <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> produces a dose-dependent increase in the QT interval, the United States Food and Drug Administration recommended that it should be reserved for patients who have not had an adequate response with other antianginal drugs [<a href="#rid15">15</a>]. We would be more restrictive, limiting the use of ranolazine to patients who have failed all other antianginal therapies. Ranolazine is contraindicated in patients with preexisting QT interval prolongation or hepatic disease, and in patients taking other drugs that prolong the QT interval or that are potent or moderately potent inhibitors of CYP3A4, such as <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>. Ranolazine also inhibits pathways involved in the metabolism of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, and dose reduction may be required.</p><p>Like other drugs that prolong the QT interval, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> inhibits the KCNH2 channel (formerly called HERG channel) [<a href="#rid16">16,17</a>]. However, the effect is generally less than with other drugs (mean QTc prolongation 2.4 ms in a review of 746 patients treated for almost three years) [<a href="#rid18">18</a>] and torsade de pointes has not yet been described [<a href="#rid15">15-19</a>]. Most drugs that cause torsade de pointes show reverse use dependence, which is defined as the inverse correlation between the heart rate and QT interval. The apparent lack of reverse use dependence with ranolazine may protect against the development of torsade de pointes [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Pathophysiology'</a>.)</p><p>In the largest reported long-term (greater than one year) experience with <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> (746 patients treated for almost three years), 10 percent discontinued therapy due to adverse events attributed to ranolazine [<a href="#rid18">18</a>]. Only advanced age (&gt;64 years) was predictive of the need to withdraw the drug. The annual mortality rate was 3.0 percent and did not exceed predicted rates.</p><p>In the MERLIN-TIMI 36 trial, treatment with <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> was associated with a 3 percent lower frequency of ventricular tachycardia (VT), a 10.3 percent lower incidence of supraventricular tachycardia, and a 0.7 percent reduction in the onset of new atrial fibrillation [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H448980795"><span class="h3">Antiarrhythmic effect</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a> has not been evaluated as a primary anti-arrhythmic agent, although it has exhibited a favorable anti-arrhythmic profile in the MERLIN-TIMI 36 Trial (see above).</p><p class="headingAnchor" id="H10"><span class="h3">Summary</span><span class="headingEndMark"> — </span>In patients with a history of chronic stable angina, including those who are stable after an acute coronary syndrome, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> is effective at reducing anginal symptoms and improving exercise capacity, when added to standard antianginal therapy. It may also be an effective anti-arrhythmic agent, although that aspect of its activity needs more extensive clinical testing.</p><p>We agree with the following weak recommendation which was made in 2012 guideline on the diagnosis and management of stable ischemic heart disease from the American College of Cardiology Foundation/American Heart Association/American College of Physicians/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS) [<a href="#rid21">21-23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a> can be a substitute for beta blockers for relief of anginal symptoms if initial treatment with beta blockers leads to unacceptable side effects or is ineffective or is contraindicated.</p><p></p><p><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a> can be combined with beta blockers for relief of symptoms if initial monotherapy with beta blockers is unsuccessful.</p><p class="headingAnchor" id="H11"><span class="h2">Inhibition of fatty acid oxidation</span><span class="headingEndMark"> — </span>Drugs in this category are rarely used for angina, and they have significant side effects. Inhibition of fatty acid oxidation represents a different approach to the management of angina. Switching from fatty acid oxidation to glucose oxidation increases cardiac metabolic efficiency. Three such agents are <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>, trimetazidine, and perhexiline [<a href="#rid24">24,25</a>]. However, ranolazine is discussed separately above because inhibition of fatty acid oxidation may not be its primary mode of action.</p><p>Although the heart uses both glucose and fatty acids as fuel, during periods of stress the heart uses more fatty acids, which is less oxygen efficient. Inhibition of fatty acid oxidation shifts the equilibrium toward increased use of glucose, improving the efficient use of oxygen.</p><p>A potential advantage of these drugs is that, in contrast to nitrates, they may be safe in patients taking <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> or other phosphodiesterase type 5 inhibitor for erectile dysfunction [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Trimetazidine</span><span class="headingEndMark"> — </span>Trimetazidine, which achieves its antiischemic action by improving the metabolic efficiency of ischemic myocardium, has not been conclusively shown to improve anginal symptomatology, and we do not use this drug. </p><p>A 2005 meta-analysis that included 23 studies of 1378 patients [<a href="#rid27">27</a>] showed that compared with placebo, trimetazidine was associated with a reduction in weekly angina episodes (mean 1.44) and improved exercise time to 1 mm ST-segment depression. Despite the reported findings, we are reluctant to make recommendations based on this 2005 study of patients who were treated using older therapies, particularly less aggressive preventive strategies. </p><p>The 2020 placebo-controlled, randomized ATPCI trial assessed the antianginal effects and safety of trimetazidine in 6007 patients who had undergone successful PCI for stable angina or non-ST-elevation myocardial infarction less than 30 days before admission to the study [<a href="#rid28">28</a>]. Trimetazidine 35 mg or placebo were administered twice daily. All patients were receiving standard preventive and antianginal therapy. After a median follow-up of 47.5 months, there was no significant difference between the two groups with respect to cardiac death, hospital admission for a cardiac event, recurrence or persistence of angina requiring an addition, switch, increase of the dose of at least one antianginal drug, or the need for repeat coronary angiography. No statistically significant increase in major side effects was reported comparing trimetazidine with placebo. </p><p class="headingAnchor" id="H13"><span class="h3">Perhexiline</span><span class="headingEndMark"> — </span>The antianginal efficacy of perhexiline was demonstrated in older trials, even in patients not controlled with other antianginal drugs [<a href="#rid24">24,25,29,30</a>]. However, its use markedly declined in the early 1980s after reports of hepatotoxicity and peripheral neuropathy [<a href="#rid25">25</a>]. These complications most often occur in patients who are slow hydroxylators and their incidence can be dramatically reduced by maintaining plasma drug concentrations between 150 and 600 ng/mL [<a href="#rid25">25,30</a>]. These findings led to increased use in some areas, such as Australia and Europe, in patients with refractory angina who are not candidates for or refuse revascularization [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Nicorandil</span><span class="headingEndMark"> — </span>Nicorandil, a potassium channel activator, is used for the treatment of angina in a number of countries, but not the United States. It has multiple actions that are beneficial in coronary artery disease. It is an arterial and venous dilator and improves coronary blood flow due to potassium channel opening and nitrate effect. Since ATP-dependent potassium channels play a role in ischemic preconditioning, nicorandil may also mimic a natural process of ischemic preconditioning, protecting the heart from subsequent ischemic attacks. (See  <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">"Myocardial ischemic conditioning: Pathogenesis"</a>.)</p><p>The effect of nicorandil (20 mg twice per day) on coronary events was evaluated in the IONA trial of 5126 patients with chronic stable angina who were receiving other standard therapies (antiplatelet drugs, beta blockers, calcium channel blockers, statins, and angiotensin converting enzyme [ACE] inhibitors) [<a href="#rid31">31</a>]. After a mean follow-up of 1.6 years, nicorandil reduced the primary end point (coronary death, nonfatal MI, or unplanned hospitalization for angina) by 17 percent (13 versus 15.5 for placebo, hazard ratio 0.83, 95% CI 0.72-0.97). There was an almost significant reduction in the secondary end point of death and nonfatal MI (4.2 versus 5.2 percent) and significant reductions in the incidence of an acute coronary syndrome (6 versus 7.6 percent) and all cardiovascular events (14.7 versus 17 percent).</p><p>IONA was an outcome study and provided little information regarding the effects of nicorandil on symptoms of angina. Worsening of anginal status was not significantly different in patients taking nicorandil compared to those on placebo (22 versus 24 percent, respectively).</p><p>Nicorandil is available in Europe and elsewhere for the treatment of angina.</p><p class="headingAnchor" id="H271903048"><span class="h2">Allopurinol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a>, a xanthine oxidase inhibitor used in the prevention of recurrent gout, should rarely be used to treat angina. </p><p>The potential use of <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> as an antianginal agent, when added to standard therapy, was evaluated in a crossover study that randomly assigned 65 patients with documented coronary artery disease to either allopurinol 600 mg per day or placebo for six weeks before crossover [<a href="#rid32">32</a>]. Allopurinol, compared to placebo, significantly increased the median time to ST depression (298 versus 249 seconds, respectively, from a baseline of 232 seconds) and median total exercise time (393 versus 307 seconds, respectively, from a baseline of 301 seconds). Further evaluation of allopurinol is necessary before it can be recommended as an antianginal agent.</p><p>The mechanism of the anti-ischemic effect of <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> was evaluated in a study of 80 patients with stable coronary artery disease (CAD) on optimal medical therapy who were randomly assigned to either allopurinol (600 mg/day) or placebo [<a href="#rid33">33</a>]. The drug significantly improved measures of endothelium-dependent vasodilation and completely abolished oxidative stress.</p><p class="headingAnchor" id="H15"><span class="h2">Endothelin receptor blockers</span><span class="headingEndMark"> — </span>Endothelin (ET)-1, which is produced by the vascular endothelium, modulates vascular tone via two receptors (ET-A and ET-B). It has been suggested that they might be valuable in patients with angina, but we do not recommend their use for this purpose, in part because have significant side effects. (See  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Endothelin'</a>.) </p><p>Endogenous endothelin causes vasoconstriction in epicardial coronary arteries in patients with coronary artery disease [<a href="#rid34">34,35</a>]. These findings suggest a possible role for endothelin antagonists, such as <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, in the treatment of angina.</p><p>However, no clinical trials to date have examined the role of endothelin receptor blockers for reducing anginal symptoms. Furthermore, selective ET-A receptor blockade may have an adverse effect. This possibility was illustrated in a report of 30 patients undergoing PCI that found that, compared with intracoronary <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, an intracoronary injection of a selective ET-A receptor blocker prevented the normal reduction in myocardial ischemia on repeat balloon inflations [<a href="#rid36">36</a>]. This may be due to a "steal effect" on collateral blood flow.</p><p class="headingAnchor" id="H16"><span class="h2">Ivabradine</span><span class="headingEndMark"> — </span>Based on the results of the SIGNIFY trial [<a href="#rid37">37</a>], we do not recommend the use of <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> in patients with stable angina who do not have clinical heart failure. </p><p>A rationale for the use of <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> emerged from data indicating that an elevated heart rate is associated with increased risk of cardiovascular events in patients with stable ischemic heart disease [<a href="#rid38">38,39</a>]. Ivabradine inhibits a specific sinus node pacemaker current, thereby lowering the heart rate. The drug has been shown to increase exercise capacity and reduce anginal frequency and severity [<a href="#rid40">40-42</a>]. Post-hoc analyses of a randomized trial have suggested that ivabradine might improve cardiovascular outcomes such as death, myocardial infarction, or hospitalization for heart failure in patients with stable disease [<a href="#rid43">43,44</a>]. However, data from SIGNIFY trial [<a href="#rid37">37</a>] fail to confirm these findings.</p><p>The SIGNIFY trial randomly assigned 19,102 patients with stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more to <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> or placebo [<a href="#rid37">37</a>]. All patients were treated with optimal medical therapy including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, statin, angiotensin converting enzyme inhibitor, and a beta blocker. The majority of patients (63 percent) had Canadian Cardiovascular Society class (CCS) II or higher angina  (<a class="graphic graphic_table graphicRef96797" href="/z/d/graphic/96797.html" rel="external">table 1</a>). The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients in the <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> group had a heart rate that was about 10 beats per minute lower than those in the placebo group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the subgroup of patients with CCS class II angina or higher, patients in the <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> group more frequently improved their CCS angina class (24.0 versus 18.8 percent; p = 0.01). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in the rate of the composite end point of cardiovascular death or nonfatal myocardial infarction after a median follow-up of about 28 months (6.8 versus 6.4 percent, respectively; HR 1.08, 95% CI 0.96-1.20). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with angina CCS II angina or higher, there was an increase in the incidence of the primary end point (7.6 versus 6.5 percent; HR 1.18, 95% CI 1.03-1.35).</p><p></p><p>While <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> improves angina in patients with CCS class II angina or higher taking optimal medical therapy, we are concerned about an increase in the risk of cardiovascular death and nonfatal myocardial infarction.</p><p class="headingAnchor" id="H17"><span class="h2">Fasudil</span><span class="headingEndMark"> — </span>Initial observational studies suggested that fasudil, an inhibitor of Rho kinase that is involved in the vascular smooth muscle contractile response, is of benefit in patients with stable and microvascular angina (ie, angina with normal coronary arteries) [<a href="#rid45">45</a>]. We do not recommend its use to treat angina.</p><p>In a multicenter, placebo-controlled trial, 84 patients with stable angina and reproducible exercise times were randomly assigned to fasudil (titrated to a dose of 80 mg twice daily) or placebo [<a href="#rid46">46</a>]. Fasudil therapy produced a significantly greater time to ≥1 mm ST segment depression at both peak (172 versus 44 s with placebo) and trough (93 versus 24 s) but no difference in time to angina, frequency of angina or <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> use, or Canadian Cardiovascular Society (CCS) functional class  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H18"><span class="h2">Testosterone</span><span class="headingEndMark"> — </span>There is some evidence that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> improves endothelial dysfunction and may be an effective antianginal agent [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/1532.html" rel="external">"Coronary endothelial dysfunction: Clinical aspects"</a>.) This was addressed in a trial of 46 men with stable angina pectoris who were randomly assigned to placebo or a daily low dose (5 mg) transdermal testosterone patch for 12 weeks, in addition to other antianginal medications [<a href="#rid48">48</a>]. Testosterone significantly increased the time to 1 mm ST segment depression on treadmill exercise testing compared to placebo (309 versus 361 s at 12 weeks).</p><p>Given the potential for side effects, further trials are warranted before <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> can be considered as a therapy for angina.</p><p class="headingAnchor" id="H19"><span class="h2">Stem cell therapy</span><span class="headingEndMark"> — </span>Transplantation of hematopoietic or bone marrow mesenchymal stem cells has been evaluated as a therapeutic option in patients after myocardial infarction or with ischemic cardiomyopathy. Its use to treat angina is investigational. (See  <a class="medical medical_review" href="/z/d/html/3478.html" rel="external">"Investigational therapies for management of heart failure", section on 'Stem cell therapy'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Therapeutic angiogenesis</span><span class="headingEndMark"> — </span>The data evaluating the possible role of therapeutic angiogenesis for refractory angina are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1537.html" rel="external">"Therapeutic angiogenesis for management of refractory angina"</a>.)</p><p>In patients with cardiovascular disease, statin therapy can reduce mortality and the incidence of acute coronary syndromes. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Our approach'</a>.) </p><p>In addition, there is increasing evidence that high-dose therapy reduces the incidence of anginal episodes in patients with stable ischemic heart disease. Two trials, AVERT and DUAAL, compared high-dose statin therapy to nonstatin-containing antianginal regimens. The applicability of these trials to current practice is unclear since statin therapy is recommended in virtually all patients with ischemic heart disease. Nevertheless, they are compatible with an antianginal effect of statin therapy. </p><p>In the AVERT trial, 80 mg of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> daily led to a reduction in the rate of hospitalization for worsening angina compared to patients treated with angioplasty but not statins [<a href="#rid49">49</a>]. In the DUAAL trial, 311 patients with stable ischemic heart disease, who were on <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other antianginal therapy, were randomly assigned to one of three treatment arms: <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> 10 mg/day; atorvastatin 80 mg/day; or amlodipine 10 mg/day plus atorvastatin 80 mg/day [<a href="#rid50">50</a>]. The primary efficacy end point, the number of ischemic episodes during 48-hour ambulatory electrocardiographic monitoring, decreased significantly from baseline (&gt;66 percent) in all three groups. There was no significant difference in outcome among the three groups, with more than 50 percent of patients becoming free of episodes of transient myocardial ischemia at 26 weeks.</p><p class="headingAnchor" id="H21"><span class="h1">NON-MEDICAL THERAPIES</span><span class="headingEndMark"> — </span>Five non-medical therapies (enhanced external counterpulsation, spinal cord stimulation, transmyocardial laser revascularization, a coronary sinus reducing device, and apheresis) have been evaluated for the treatment of refractory angina.</p><p class="headingAnchor" id="H22"><span class="h2">External counterpulsation</span><span class="headingEndMark"> — </span>External counterpulsation (ECP), also referred to as enhanced external counterpulsation (EECP), is a technique that increases arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). Cuffs are wrapped around the patient’s calves, thighs, and pelvis and, using compressed air, sequential pressure (up to 300 mmHg) is applied in early diastole to propel blood back to the heart.</p><p>The efficacy of ECP was evaluated in the MUST-EECP trial, which randomly assigned 139 outpatients with angina, documented coronary artery disease, and a positive exercise tolerance test to 35 hours of active EECP using a cuff pressure of 300 mmHg or inactive counterpulsation using a cuff pressure of 75 mmHg over a four- to seven-week period of time [<a href="#rid51">51</a>]. The following results were seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Active EECP was well tolerated without limiting side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise duration increased to a similar degree in both the active and inactive EECP groups; there was also no significant difference in <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients undergoing active EECP had a significant increase in time to ≥1 mm ST segment depression compared to baseline (379 versus 337 seconds), while there was no change in the inactive group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More patients undergoing active EECP had a decrease in anginal episodes and fewer had an increase in angina compared to the inactive group.</p><p></p><p>Similar findings have been noted in multicenter registries [<a href="#rid52">52,53</a>]. In a series of 363 patients, 72 percent improved from severe to no or mild angina and 52 percent discontinued the use of <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> [<a href="#rid53">53</a>]. At two years, the decrease in angina persisted in 55 percent of patients, survival was 83 percent, and major adverse cardiac event-free survival was 70 percent. Repeat ECP was required in 20 percent.</p><p>The mechanism of these benefits is not clear, but is probably related, at least in part, to improvements in stress-induced myocardial perfusion, left ventricular diastolic filling, peripheral arterial flow-mediated dilation [<a href="#rid54">54</a>], and endothelial function [<a href="#rid54">54-59</a>].</p><p>The 2014 American College of Cardiology/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons focused update on prior stable ischemic heart states that ECP may be considered for relief of refractory angina [<a href="#rid21">21-23</a>]. ECP has met with only limited acceptance in practice.</p><p>The Centers of Medicare and Medicaid Services (CMS) in the United States have approved payment for ECP in patients with Canadian Cardiovascular Society class III or IV angina  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>) who, in the opinion of a cardiologist or cardiovascular surgeon, are not readily amenable to percutaneous coronary intervention or coronary artery bypass graft surgery because the patient is inoperable or at high risk for complications, or the coronary anatomy is not suitable for revascularization [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Spinal cord stimulation</span><span class="headingEndMark"> — </span>Despite advances in medical and surgical therapies for angina patients, there remains a small number of patients with refractory angina. Spinal cord stimulation at the T1 to T2 level is another approach to the management of refractory angina. Spinal cord stimulation was originally developed to treat neurogenic pain and then applied to the refractory angina population. While the approach is clearly effective in some, objective evidence of its efficacy is not compelling. Studies of this therapy tend to be small and open label randomized trials or observational studies [<a href="#rid61">61-64</a>].</p><p>Its mechanism of action is poorly understood. This technique may have beneficial effects on angina by suppressing the capacity of intrinsic cardiac neurons to generate activity during myocardial ischemia [<a href="#rid65">65</a>]; alternatively, it may provide benefit by reducing sympathetic activity or by redistributing myocardial blood flow from nonischemic to ischemic areas [<a href="#rid66">66</a>].</p><p>In the largest trial (ESBY), 104 patients at high risk for surgery were randomly assigned to coronary artery bypass graft surgery (CABG) or spinal cord stimulation [<a href="#rid61">61</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Both techniques reduced angina and the use of nitrates to a similar extent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CABG group had a greater increase in exercise capacity, less ST-segment depression at maximum and comparable workloads, and an increase in the rate-pressure product both at maximum and comparable workloads compared to the group receiving spinal cord stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, spinal cord stimulation was associated with a lower six-month mortality (1.9 versus 13.7 percent with CABG) and fewer cerebrovascular events (3.8 versus 15.7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At later follow-up, cessation of spinal cord stimulation was associated with a lack of effect on ischemic ST changes but a reduction in anginal symptoms, suggesting a primary analgesic effect [<a href="#rid62">62</a>].</p><p></p><p>The SPiRiT trial compared spinal cord stimulation to percutaneous myocardial laser revascularization in 60 patients with refractory angina [<a href="#rid63">63</a>]. There was no significant difference between the groups in terms of the primary end point of total exercise time or in other parameters such as CCS functional class  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>). Although CCS functional class improved by ≥2 CCS classes at one year in about 25 percent of patients in both groups, there was no placebo control. This is an important limitation, since the only blinded, placebo-controlled trial of percutaneous transmyocardial laser revascularization (DIRECT), using low-dose or high-dose laser channels or no laser channels blinded as a sham procedure, showed no benefit [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/1568.html" rel="external">"Transmyocardial laser revascularization for management of refractory angina"</a>.)</p><p>Some patients with cardiac syndrome X (angina with normal coronary arteries) have frequent episodes of severe chest pain that are refractory to maximal antianginal therapy. In a small randomized crossover trial of 10 such patients, spinal cord stimulation reduced the number, duration, and severity of spontaneous anginal episodes and prolonged the time to angina and to ST segment depression during <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries", section on 'Management of refractory angina'</a>.)</p><p>Overall, spinal cord stimulation is an unproven procedure given the current state of knowledge. It should be reserved for a few carefully selected patients, if any.</p><p class="headingAnchor" id="H24"><span class="h2">Transmyocardial laser revascularization</span><span class="headingEndMark"> — </span>The data evaluating the efficacy of transmyocardial laser revascularization in the treatment of refractory angina are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1568.html" rel="external">"Transmyocardial laser revascularization for management of refractory angina"</a>.)</p><p class="headingAnchor" id="H543031913"><span class="h2">Coronary sinus reducing device</span><span class="headingEndMark"> — </span>A coronary sinus reducing device has been shown to improve outcomes in patients with refractory angina [<a href="#rid69">69</a>]. This device is mounted on a balloon catheter and inserted into the coronary sinus percutaneously. Balloon expansion leads to the permanent implantation of an hourglass-shaped metal mesh that leads, over time, to partial obstruction of the coronary sinus. It is postulated that the development of an upstream pressure gradient favors perfusion of ischemic territories.</p><p>In the small, phase 2 COSIRA trial, 104 patients with Canadian Cardiovascular Society (CCS) class III or IV refractory angina  (<a class="graphic graphic_table graphicRef96797" href="/z/d/graphic/96797.html" rel="external">table 1</a>) and documented myocardial ischemia were randomly assigned to the device or a sham procedure [<a href="#rid70">70</a>]. The primary end point of the proportion of patients with an improvement of at least two CCS angina classes at six months occurred more frequently in the device group (35 versus 15 percent; p=0.02). In addition, quality of life, as assessed with the Seattle Angina Questionnaire was improved in the treatment group, as compared with the control group. Adverse outcomes such as myocardial infarction or death did not appear to differ significantly between the groups.</p><p class="headingAnchor" id="H1391466699"><span class="h2">Apheresis</span><span class="headingEndMark"> — </span>The potential role of apheresis in the treatment of patients with refractory angina and a significantly elevated level of lipoprotein(a) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">"Lipoprotein(a)", section on 'Lipoprotein apheresis'</a> and  <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">"Lipoprotein(a)"</a>.)</p><p class="headingAnchor" id="H389464032"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a>.)</p><p class="headingAnchor" id="H248875372"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86017.html" rel="external">"Patient education: Medicines for angina (chest pain) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H102066498"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– Most patients with stable angina pectoris can have an acceptable frequency (and severity) of angina with conventional medical therapies, such as beta blockers, calcium channel blockers, nitrates, and/or myocardial revascularization with either percutaneous coronary intervention (PCI) or coronary bypass graft surgery (CABG). For these patients for whom angina remains problematic, a number of medical and mechanical therapies have been evaluated for the treatment of refractory angina. Only <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> has demonstrated significant efficacy in large trials. (See <a class="local">'Medical therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a><strong> </strong>– Ranolazine is effective at reducing anginal symptoms and improving exercise capacity when added to conventional medical therapy. The initial dose is 500 mg twice daily. For patients who remain symptomatic, 1000 mg twice daily may be used. (See <a class="local">'Ranolazine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emerging therapies </strong>– Other medical therapies such as fatty acid oxidation inhibitors or nicorandil have demonstrated some efficacy in studies. Until further supporting evidence is available, our authors do not recommend their use for the prevention of anginal episodes. (See <a class="local">'Medical therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>External counterpulsation </strong>– This is the best studied of possible mechanical therapies to improve angina. While approved for use in some countries, it is not widely used. (See <a class="local">'Non-medical therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 23:355.</a></li><li><a class="nounderline abstract_t">Kim MC, Kini A, Sharma SK. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 2002; 39:923.</a></li><li><a class="nounderline abstract_t">Yang EH, Barsness GW, Gersh BJ, et al. Current and future treatment strategies for refractory angina. Mayo Clin Proc 2004; 79:1284.</a></li><li><a class="nounderline abstract_t">Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113:2462.</a></li><li><a class="nounderline abstract_t">Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation 2012; 125:2698.</a></li><li><a class="nounderline abstract_t">Stone PH. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin 2008; 26:603.</a></li><li><a class="nounderline abstract_t">Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297:1775.</a></li><li><a class="nounderline abstract_t">Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291:309.</a></li><li><a class="nounderline abstract_t">Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48:566.</a></li><li><a class="nounderline abstract_t">Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43:1375.</a></li><li><a class="nounderline abstract_t">Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 2013; 61:2038.</a></li><li><a class="nounderline abstract_t">Weisz G, Généreux P, Iñiguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387:136.</a></li><li><a class="nounderline abstract_t">Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53:1510.</a></li><li><a class="nounderline abstract_t">Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009; 119:2032.</a></li><li><a class="nounderline abstract_t">"The Pink Sheet". Ranexa angina approval limited due to cardiac safety issue. F-D-C Reports 2006; 68:3.</a></li><li><a class="nounderline abstract_t">Schram G, Zhang L, Derakhchan K, et al. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142:1300.</a></li><li><a class="nounderline abstract_t">Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004; 9 Suppl 1:S65.</a></li><li><a class="nounderline abstract_t">Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007; 49:1027.</a></li><li><a class="nounderline abstract_t">Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004; 9 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647.</a></li><li><a class="nounderline abstract_t">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.</a></li><li><a class="nounderline abstract_t">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.</a></li><li><a class="nounderline abstract_t">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929.</a></li><li><a class="nounderline abstract_t">Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005; 112:3218.</a></li><li><a class="nounderline abstract_t">Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25:634.</a></li><li><a class="nounderline abstract_t">Rosano GM, Marazzi G, Patrizi R, et al. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 2005; 95:327.</a></li><li><a class="nounderline abstract_t">Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; :CD003614.</a></li><li><a class="nounderline abstract_t">Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet 2020; 396:830.</a></li><li><a class="nounderline abstract_t">White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3:145.</a></li><li><a class="nounderline abstract_t">Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81:1260.</a></li><li><a class="nounderline abstract_t">IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359:1269.</a></li><li><a class="nounderline abstract_t">Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375:2161.</a></li><li><a class="nounderline abstract_t">Rajendra NS, Ireland S, George J, et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011; 58:820.</a></li><li><a class="nounderline abstract_t">Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104:1114.</a></li><li><a class="nounderline abstract_t">Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235.</a></li><li><a class="nounderline abstract_t">Kyriakides ZS, Kremastinos DT, Kolettis TM, et al. Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation 2000; 102:1937.</a></li><li><a class="nounderline abstract_t">Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371:1091.</a></li><li><a class="nounderline abstract_t">Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26:967.</a></li><li><a class="nounderline abstract_t">Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:1327.</a></li><li><a class="nounderline abstract_t">Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107:817.</a></li><li><a class="nounderline abstract_t">Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26:2529.</a></li><li><a class="nounderline abstract_t">Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30:540.</a></li><li><a class="nounderline abstract_t">Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:807.</a></li><li><a class="nounderline abstract_t">Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30:2337.</a></li><li><a class="nounderline abstract_t">Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003; 41:15.</a></li><li><a class="nounderline abstract_t">Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46:1803.</a></li><li><a class="nounderline abstract_t">Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99:1666.</a></li><li><a class="nounderline abstract_t">English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102:1906.</a></li><li><a class="nounderline abstract_t">Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341:70.</a></li><li><a class="nounderline abstract_t">Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J 2010; 31:2650.</a></li><li><a class="nounderline abstract_t">Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999; 33:1833.</a></li><li><a class="nounderline abstract_t">Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology 2000; 94:31.</a></li><li><a class="nounderline abstract_t">Soran O, Kennard ED, Kfoury AG, et al. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). Am J Cardiol 2006; 97:17.</a></li><li><a class="nounderline abstract_t">Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation 2010; 122:1612.</a></li><li><a class="nounderline abstract_t">Urano H, Ikeda H, Ueno T, et al. Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol 2001; 37:93.</a></li><li><a class="nounderline abstract_t">Stys TP, Lawson WE, Hui JC, et al. Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris. Am J Cardiol 2002; 89:822.</a></li><li><a class="nounderline abstract_t">Shechter M, Matetzky S, Feinberg MS, et al. External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol 2003; 42:2090.</a></li><li><a class="nounderline abstract_t">Akhtar M, Wu GF, Du ZM, et al. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Am J Cardiol 2006; 98:28.</a></li><li><a class="nounderline abstract_t">Nichols WW, Estrada JC, Braith RW, et al. Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina. J Am Coll Cardiol 2006; 48:1208.</a></li><li class="breakAll">www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=20.20&amp;ncd_version=2&amp;basket=ncd%3A20%2E20%3A2%3AExternal+Counterpulsation+%28ECP%29+for+Severe+Angina (Accessed on August 01, 2006).</li><li><a class="nounderline abstract_t">Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 1998; 97:1157.</a></li><li><a class="nounderline abstract_t">Norrsell H, Pilhall M, Eliasson T, Mannheimer C. Effects of spinal cord stimulation and coronary artery bypass grafting on myocardial ischemia and heart rate variability: further results from the ESBY study. Cardiology 2000; 94:12.</a></li><li><a class="nounderline abstract_t">McNab D, Khan SN, Sharples LD, et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J 2006; 27:1048.</a></li><li><a class="nounderline abstract_t">Eckert S, Horstkotte D. Management of angina pectoris: the role of spinal cord stimulation. Am J Cardiovasc Drugs 2009; 9:17.</a></li><li><a class="nounderline abstract_t">Foreman RD, Linderoth B, Ardell JL, et al. Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris. Cardiovasc Res 2000; 47:367.</a></li><li><a class="nounderline abstract_t">Murray S, Collins PD, James MA. Neurostimulation treatment for angina pectoris. Heart 2000; 83:217.</a></li><li><a class="nounderline abstract_t">Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005; 46:1812.</a></li><li><a class="nounderline abstract_t">Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005; 26:983.</a></li><li><a class="nounderline abstract_t">Banai S, Ben Muvhar S, Parikh KH, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol 2007; 49:1783.</a></li><li><a class="nounderline abstract_t">Verheye S, Jolicœur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med 2015; 372:519.</a></li></ol></div><div id="topicVersionRevision">Topic 1524 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11846493" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897431" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Refractory angina pectoris: mechanism and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473411" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current and future treatment strategies for refractory angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717165" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22565935" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929234" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456819" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734593" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875985" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093870" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23500237" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474810" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389561" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349325" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ranexa angina approval limited due to cardiac safety issue</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277312" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15378132" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349881" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15378133" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804441" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23166211" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23166210" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25077860" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301353" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084367" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15670539" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235330" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trimetazidine for stable angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877651" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134684" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2180591" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965271" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542554" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835317" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11535565" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826308" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034942" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176136" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ivabradine in stable coronary artery disease without clinical heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774493" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375982" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591750" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214830" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136486" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757088" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720635" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570938" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286163" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190874" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute anti-ischemic effect of testosterone in men with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034937" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10395630" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494902" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362181" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11111142" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment benefit in the enhanced external counterpulsation consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377276" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921442" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153780" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11909566" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14680732" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16784915" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979007" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979007" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537342" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11111139" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of spinal cord stimulation and coronary artery bypass grafting on myocardial ischemia and heart rate variability: further results from the ESBY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554313" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178129" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management of angina pectoris: the role of spinal cord stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946073" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648501" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neurostimulation treatment for angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286164" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642701" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466229" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651246" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of a device to narrow the coronary sinus in refractory angina.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
